ALGS

Aligos Therapeutics, Inc. (ALGS) ESG Analysis Analysis (2026)

Invetso Score: 6.3/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.8 (Moderate)

ALGS appears more R&D-intensive than many peers, which can support lower-emission product innovation, but the provided metrics do not evidence operational decarbonization leadership.

The very high gross margin suggests a lighter direct manufacturing footprint than asset-heavy peers, yet no emissions, energy, or waste disclosures are provided to confirm superior environmental management.

Low leverage can reduce environmental compliance strain and funding pressure versus more indebted peers, but it does not itself indicate stronger environmental controls or targets.

Absence of disclosed environmental KPIs in the supplied data limits evidence of peer-leading climate governance, so positioning remains broadly middle-of-pack rather than advantaged.

Social

Score:

High R&D intensity can indicate stronger human-capital reliance and knowledge work versus peers, which may support workforce quality, but no retention or safety data are provided.

Stock-based compensation at a meaningful level can align employees with long-term value creation, though it may also dilute perceived pay fairness relative to peers if not well managed.

The capital-light profile implied by low leverage may reduce restructuring pressure on employees versus more financially stressed peers, but this is an indirect social benefit only.

No metrics on diversity, turnover, training, or product responsibility are supplied, so the social profile cannot be assessed as clearly stronger than peer norms.

Governance

Score:

Low debt-to-equity and net debt-to-EBITDA suggest conservative balance-sheet governance versus more leveraged peers, reducing refinancing and covenant risk.

R&D spending near 2.8% of revenue indicates disciplined reinvestment, but the data do not show whether capital allocation is superior to peers on a governance basis.

Stock-based compensation at 17.8% of revenue is material and may pressure governance quality versus peers if dilution is not tightly controlled.

No board, audit, ownership, or controversy data are provided, so governance appears prudent but not demonstrably leading relative to peers.

Overall Score

Score:

ALGS screens as a mid-tier ESG performer versus peers, with conservative leverage supporting governance and limited evidence of environmental or social leadership.

Score Driver: Conservative Leverage Is The Clearest Relative Strength, While Missing ESG Disclosure Prevents A Stronger Peer-Relative Assessment.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Aligos Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →